

15. If the Licensee shall, in the sale or distribution of said product, fail to use safe, efficient and adequate methods, or shall sell or distribute any product which fails to comply with the standards of strength, stability, composition and purity from time to time fixed by the Licensor, the Licensor, by sixty (60) days prior written notice sent by registered mail, addressed to the Licensee, may suspend the license hereby granted, and all rights and privileges hereby conferred until the requirements of the Licensor as to methods and standards are complied with by the Licensee to the satisfaction of the Licensor.

16. If the Licensee, after receiving any such notice, shall for six months fail to meet the established standards of strength, stability, composition or purity of said product, the Licensor shall (notwithstanding any waiver by the Licensor or any failure by the Licensor to take advantage of any prior conditions, failures or defaults) have the right to terminate forthwith the license hereby granted.

17. No new product covered hereby or special literature describing the same shall be released by the Licensee without the consent and approval of the Licensor being first obtained, should he so desire and so instruct in writing. All advertisements in medical and pharmaceutical journals and in the general advertising of the Licensor shall be based only upon statements appearing in the special literature which has had the approval of the Licensor.

18. The Licensee shall, at all times, sell the product covered hereby at moderate, fair and reasonable prices, consistent with manufacturing and market conditions then existing. If the Licensor believes that the

Licensor's
Control of
Literature

Control of
Price